An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 021252
Company: ABBVIE

Products on NDA 021252

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CANASA	MESALAMINE	500MG	SUPPOSITORY;RECTAL	Discontinued	None	No	No
CANASA	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 021252

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
01/05/2001	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21252lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/21252ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-252_Canasa.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/24/2023	SUPPL-30	Labeling-Package Insert, Labeling-Medication Guide	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/021252Orig1s030ltr.pdf
11/16/2022	SUPPL-29	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021252s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/021252Orig1s029ltr.pdf
11/01/2021	SUPPL-28	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/021252Orig1s028ltr.pdf
10/01/2020	SUPPL-25	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/021252Orig1s025ltr.pdf
07/27/2017	SUPPL-23	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021252s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/021252Orig1s023ltr.pdf
07/30/2014	SUPPL-21	Manufacturing (CMC)		Label is not available on this site.
12/17/2013	SUPPL-20	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021252Orig1s020ltr.pdf
01/02/2014	SUPPL-19	Manufacturing (CMC)		Label is not available on this site.
12/24/2013	SUPPL-18	Manufacturing (CMC)		Label is not available on this site.
05/03/2013	SUPPL-16	Manufacturing (CMC)		Label is not available on this site.
09/02/2016	SUPPL-14	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021252s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/021252Orig1s014ltr.pdf
02/06/2013	SUPPL-13	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021252Orig1s013ltr.pdf
05/23/2008	SUPPL-9	Labeling-Container/Carton Labels, Labeling-Package Insert	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021252s009ltr.pdf
06/08/2006	SUPPL-7	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021252s007LTR.pdf
09/23/2004	SUPPL-6	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21252s006ltr.pdf
11/05/2004	SUPPL-5	Efficacy-New Dosing Regimen	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21252s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21252s005ltr.pdf
10/14/2003	SUPPL-2	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21252slr002ltr.pdf

Labels for NDA 021252

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/24/2023	SUPPL-30	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf
10/24/2023	SUPPL-30	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021252s030lbl.pdf
11/16/2022	SUPPL-29	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021252s029lbl.pdf
11/01/2021	SUPPL-28	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf
11/01/2021	SUPPL-28	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021252s028lbl.pdf
10/01/2020	SUPPL-25	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf
10/01/2020	SUPPL-25	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021252s025lbl.pdf
07/27/2017	SUPPL-23	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021252s023lbl.pdf
09/02/2016	SUPPL-14	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021252s014lbl.pdf
12/17/2013	SUPPL-20	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s020lbl.pdf
02/06/2013	SUPPL-13	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021252s013lbl.pdf
11/05/2004	SUPPL-5	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21252s005lbl.pdf
01/05/2001	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21252lbl.pdf

Therapeutic Equivalents for NDA 021252

CANASA

SUPPOSITORY;RECTAL; 1GM
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CANASA	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	Yes	AB	021252	ABBVIE
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	205654	ACTAVIS MID ATLANTIC
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	213377	ANNORA PHARMA
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	208362	J MOLNER
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	204354	QUAGEN
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	207448	RISING
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	219028	RISING
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	202065	SANDOZ
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	208953	ZYDUS PHARMS

Top